One of the prominent roles of a body's immune system is its ability to differentiate between normal cells and foreign cells like bacteria, viruses, germs, & even cancer cells. The immune system uses checkpoint proteins on the immune cells to attack the foreign cells without affecting the normal ones. The checkpoints behave like switches that turn on or off a response.
However, sometimes the cancer cells outwit the immune system and spread in the body. It is where immune checkpoint inhibitors come into the picture, where they use the body's immune system and turn it on to target the cancer cells. These inhibitors are known for attacking potentially harmful agents. In the case where immune response begins affecting healthy tissues, the system can be turned off in order to prevent the damage.
While immune checkpoint inhibitors do not kill the cancer cells directly, they find ways to help the immune system find & attack the cells throughout the body. With rapid advancements in checkpoint inhibitors, these proteins can now also be used for the treatment of a few cancers by infusing drugs into the vein.
The Global Immune Checkpoint Inhibitors Market is projected to grow at a CAGR of around 17% during the forecast period, i.e., 2022-27. The growth of the market would be driven primarily by the rapidly increasing incidence of cancer worldwide & the mounting demand for effective & safe treatments, i.e., instigating governments to enhance the healthcare infrastructure to cater to the high unmet patient needs.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: The US, Canada, Mexico|
|Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe|
|Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific|
|South America: Brazil, Rest of Latin America|
|Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa|
|Key Companies Profiled||
AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Others
|Unit Denominations||USD Million/Billion|
In addition, since the advent of immune checkpoint inhibitors, cancer treatment has witnessed a revolution in the past years and even demonstrated alternation in outcomes for various cancers, including Malignant Melanoma & Non-Small Cell Lung Cancer. This aspect is playing a prominent role in instigating the leading biopharma companies to conduct rigorous research & development activities to bring innovations in immune checkpoint inhibitors and introduce novel drugs for greater efficacy & safety.
Besides, the growing adoption of immune checkpoint inhibitors for preventing cancer cells from turning off T lymphocytes (T cells) is also elevating their demand and augmenting the overall market growth. T cells are a kind of immune system cells that kill cancer and have receptors on their surfaces from where other cells stick & turn them on or off. In some cases, the cancer cells bind with the receptors on activated T cells and turn them off. However, immune checkpoint inhibitors prevent the cancer cells from doing so & allow T cells to infiltrate the tumor while eliminating its growth. Hence, due to such benefits, the demand for immune checkpoint inhibitors is rising rapidly for their application in various cancer treatments and stimulating the expansion of the global market.
Moreover, growing awareness among patients about their benefits, like fewer side effects & targeted therapeutic effects, is another prominent aspect contributing to the mounting demand for immune checkpoint inhibitors worldwide. It, in turn, is also attracting massive funding from various pharmaceuticals, biotech companies, universities, & cancer centers in the research & development of more effective immune checkpoint inhibitors and fueling the overall market growth.